Laboratorio Reig Jofre

Laboratorio Reig Jofre

RJF.MCPre-clinical
Founded 1929reigjofre.com

Laboratorio Reig Jofre is a nearly century-old Spanish pharmaceutical company with a mission to universalize access to essential health solutions. It has evolved from a national player into an international organization with commercial and manufacturing operations across Europe and Asia, driven by a strategy of innovation, vertical integration in biotech manufacturing, and leveraging advanced technologies like its patented CicloTech® delivery system. The company is publicly listed on the Spanish stock exchange and is followed by several financial analysts, reflecting its established position in the market.

Market Cap
$992.6M
Founded
1929
Focus
Generic Drugs

RJF.MC · Stock Price

USD 13.800.80 (-5.48%)

Historical price data

AI Company Overview

Laboratorio Reig Jofre is a nearly century-old Spanish pharmaceutical company with a mission to universalize access to essential health solutions. It has evolved from a national player into an international organization with commercial and manufacturing operations across Europe and Asia, driven by a strategy of innovation, vertical integration in biotech manufacturing, and leveraging advanced technologies like its patented CicloTech® delivery system. The company is publicly listed on the Spanish stock exchange and is followed by several financial analysts, reflecting its established position in the market.

Technology Platform

Patented CicloTech® trans-ungual drug delivery technology for dermatology and advanced manufacturing capabilities for sterile injectables and biotechnological drugs through vertical integration.

Funding History

1
IPOUndisclosedUndisclosedJun 15, 1998

Opportunities

Significant growth opportunities exist in the international expansion of its commercial footprint, particularly in Asia via its Singapore JV and Chinese e-commerce.
The vertical integration into biotech CDMO services through Leanbio positions the company in a high-growth sector with substantial demand from biopharma innovators.

Risk Factors

Key risks include execution challenges in new international markets, intense competition in the biologics CDMO space, reliance on the successful commercialization of new products like Vincobiosis®, and ongoing regulatory and pricing pressures inherent to the global pharmaceutical industry.

Competitive Landscape

Competes with multinational pharma giants in essential medicines, specialized European mid-cap pharma companies, and established CDMOs in biologics manufacturing. Differentiation is achieved through a hybrid model of stable commercial products, niche drug delivery technology (CicloTech®), and strategic vertical integration into advanced manufacturing.

Company Info

TypeTherapeutics
Founded1929
LocationSpain
StagePre-clinical
RevenueRevenue Generating

Trading

TickerRJF.MC
ExchangeBME (Bolsas y Mercados Españoles)

Therapeutic Areas

DermatologyHospital & Critical CareConsumer Health & WellnessBiologics Manufacturing

Partners

European Commission (vaccine capacity)Farmamundi (international NGO)LeanbioSyna Therapeutics
SIMILAR COMPANIES
A4Cell
A4Cell
Pre-clinical · Barcelona
Ability Pharma
Ability Pharma
Phase 2 · Barcelona
Abyntek Biopharma
Abyntek Biopharma
Pre-clinical · Derio
Acellera
Acellera
Pre-clinical · Barcelona
BeCytes Biotechnologies
BeCytes Biotechnologies
Pre-clinical · Barcelona
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile